Shares of NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $8.83 and last traded at $8.95, with a volume of 59626 shares trading hands. The stock had previously closed at $9.42.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on the company. Bank of America reduced their price target on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 19th. Benchmark lowered NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Needham & Company LLC dropped their price target on NeoGenomics from $19.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, February 19th. Piper Sandler cut their price objective on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Jefferies Financial Group began coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $19.60.
Read Our Latest Stock Analysis on NeoGenomics
NeoGenomics Price Performance
The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -13.59 and a beta of 1.41. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The business's 50-day simple moving average is $11.26 and its two-hundred day simple moving average is $14.04.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.05). The firm had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. Research analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.
Hedge Funds Weigh In On NeoGenomics
Several large investors have recently modified their holdings of NEO. Vanguard Group Inc. increased its holdings in NeoGenomics by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company's stock valued at $234,673,000 after purchasing an additional 195,793 shares during the period. State Street Corp raised its position in shares of NeoGenomics by 1.6% during the third quarter. State Street Corp now owns 4,958,582 shares of the medical research company's stock worth $73,139,000 after acquiring an additional 80,449 shares during the last quarter. Greenhouse Funds LLLP lifted its stake in shares of NeoGenomics by 5.3% in the fourth quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock worth $77,487,000 after acquiring an additional 237,491 shares during the period. Dimensional Fund Advisors LP increased its position in NeoGenomics by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,436,858 shares of the medical research company's stock valued at $56,645,000 after purchasing an additional 78,211 shares during the period. Finally, First Light Asset Management LLC raised its holdings in NeoGenomics by 3.0% during the 4th quarter. First Light Asset Management LLC now owns 3,167,585 shares of the medical research company's stock worth $52,202,000 after purchasing an additional 91,030 shares during the last quarter. Institutional investors own 98.50% of the company's stock.
About NeoGenomics
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
See Also
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
